5093 Head and neck region of the ectodomain of paramyxoviruses fusion glycoprotein
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous non-metal compounds | 3 | 5.3 | 0.56× | q = 0.41 | |
| Homogeneous metal compounds | 2 | 12.1 | 0.17× | q < 0.0001 | |
| Nucleosides, nucleotides, and analogues | 0 | 6.8 | 0 | q = 1.3e-3 | |
| Organic oxygen compounds | 24 | 4.9 | 4.89× | not tested | |
| Organic nitrogen compounds | 2 | 0.8 | 2.54× | not tested | |
| Organoheterocyclic compounds | 4 | 3.8 | 1.05× | not tested | |
| Benzenoids | 1 | 1.8 | 0.56× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 155 |
| DB03309 | NHE | N-cyclohexyltaurine | 25 |
| DB01694 | TAR | D-tartaric acid | 9 |
| DB03740 | NDG | N-acetyl-alpha-D-glucosamine | 2 |
| DB15672 | 6YA | Rilematovir | 1 |
| DB15674 | WVA | Sisunatovir | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 169 |
| NHE | 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID | 25 |
| CL | CHLORIDE ION | 12 |
| TAR | D(-)-TARTARIC ACID | 9 |
| ZNmetal | ZINC ION | 4 |
| 336 | 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE | 3 |
| 5NK | 2-[[2-[[1-(2-azanylethyl)piperidin-4-yl]amino]-4-methyl-benzimidazol-1-yl]methyl]-6-methyl-pyridin-3-ol | 3 |
| CDmetal | CADMIUM ION | 3 |
| NDG | 2-acetamido-2-deoxy-alpha-D-glucopyranose | 2 |
| TM3 | 2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol | 2 |
| 5NM | 3-[[5-bromanyl-1-(3-methylsulfonylpropyl)benzimidazol-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one | 1 |
| 5NO | 1-cyclopropyl-3-[[1-(4-oxidanylbutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one | 1 |
| 5NP | (9~{b}~{R})-9~{b}-(4-chlorophenyl)-1-pyridin-3-ylcarbonyl-2,3-dihydroimidazo[5,6]pyrrolo[1,2-~{a}]pyridin-5-one | 1 |
| 6YA | 3-[[5-chloranyl-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-[2,2,2-tris(fluoranyl)ethyl]imidazo[4,5-c]pyridin-2-one | 1 |
| 95C | 4-nitro-2-[(phenylacetyl)amino]benzamide | 1 |
| A1APZ | 1'-{[5-chloro-1-(4,4,4-trifluorobutyl)-1H-1,3-benzimidazol-2-yl]methyl}-1-(methanesulfonyl)spiro[azetidine-3,3'-indol]-2'(1'H)-one | 1 |
| NImetal | NICKEL (II) ION | 1 |
| R0J | 3-{[5-chloro-1-(4,4,4-trifluorobutyl)-1H-imidazo[4,5-b]pyridin-2-yl]methyl}-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one | 1 |
| R0P | 1-cyclopropyl-3-({1-[3-(methylsulfonyl)propyl]-1H-pyrrolo[3,2-c]pyridin-2-yl}methyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one | 1 |
| R0S | 4-(5-chloro-2-{[1-(3,4-dimethoxyphenyl)-2-oxo-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl]methyl}-1H-indol-1-yl)butanenitrile | 1 |